Researchers in the UK are hoping to develop a rapid, saliva-based test that could identify stroke patients who need rapid treatment to prevent irreversible brain damage.
With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially
Digital health company Cumulus Neuroscience has teamed up with two UK universities to develop its at-home electroencephalogram (EEG) headset as an early warning system for
The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.